IL97909A - Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences - Google Patents

Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Info

Publication number
IL97909A
IL97909A IL97909A IL9790991A IL97909A IL 97909 A IL97909 A IL 97909A IL 97909 A IL97909 A IL 97909A IL 9790991 A IL9790991 A IL 9790991A IL 97909 A IL97909 A IL 97909A
Authority
IL
Israel
Prior art keywords
consequences
treatment
pharmaceutical compositions
monoclonal antibodies
compositions containing
Prior art date
Application number
IL97909A
Other languages
English (en)
Other versions
IL97909A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL97909A0 publication Critical patent/IL97909A0/xx
Publication of IL97909A publication Critical patent/IL97909A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL97909A 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences IL97909A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (de) 1990-04-25 1990-11-27 Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen

Publications (2)

Publication Number Publication Date
IL97909A0 IL97909A0 (en) 1992-06-21
IL97909A true IL97909A (en) 1997-09-30

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97909A IL97909A (en) 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Country Status (7)

Country Link
EP (1) EP0453898B1 (fr)
JP (1) JPH04364133A (fr)
AT (1) ATE123226T1 (fr)
DE (2) DE4037604A1 (fr)
DK (1) DK0453898T3 (fr)
ES (1) ES2073059T3 (fr)
IL (1) IL97909A (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (fr) 1989-08-07 2001-03-07 Peptech Limited Ligands de liaison du facteur de necrose de tumeurs
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
MX2007014440A (es) 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
EP2004689A4 (fr) 2006-04-05 2010-06-02 Abbott Biotech Ltd Purification d'anticorps
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (fr) 2015-03-30 2016-10-06 Abbvie Inc. Protéines de liaison au tnf monovalentes
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
WO1990000902A1 (fr) * 1988-07-18 1990-02-08 Chiron Corporation Anticorps monoclonaux reagissant avec la cachetine

Also Published As

Publication number Publication date
JPH04364133A (ja) 1992-12-16
DE59105609D1 (de) 1995-07-06
EP0453898A3 (en) 1991-12-18
ES2073059T3 (es) 1995-08-01
EP0453898B1 (fr) 1995-05-31
DK0453898T3 (da) 1995-10-09
IL97909A0 (en) 1992-06-21
EP0453898A2 (fr) 1991-10-30
ATE123226T1 (de) 1995-06-15
DE4037604A1 (de) 1991-10-31

Similar Documents

Publication Publication Date Title
IL97909A (en) Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
ATE177011T1 (de) Cdw52-spezifischer antikörper zur behandlung von multipler sklerose
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
DE69316948D1 (de) Lösliche Liganden für CD40
ATE439137T1 (de) Behandlung von hämatologischen störungen
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
GR3026219T3 (en) Mouse monoclonal antibodies
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
DE69333711D1 (de) Compactin zur behandlung von entzündungen
DE69314234D1 (de) Konservierte Polysiloxanemulsion zur Behandlung von Geweben
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
TW223019B (fr)
ATA119394A (de) Verwendung von humanem protein c zur verhinderung und behandlung von thrombozytenablagerungen
DE59200730D1 (de) Verfahren zur Herstellung von N-[(2-Chlor-pyridin-5-yl)methyl]-ethylendiamin.
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
ES2088820A1 (es) Anticuerpos monoclonales antineumolisina.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees